Skip to content

PTSD research published in 2022

Page 2 of 5: studies 21 to 40 of 87, newest first. Back to the PTSD overview

Studies

Effects of Selective Serotonin Reuptake Inhibitor Use on 3,4-Methylenedioxymethamphetamine–Assisted Therapy for Posttraumatic Stress Disorder

Journal of Clinical Psychopharmacology September 1, 2022 Collin M. Price, Allison A. Feduccia, Katrina Debonis

Abstract Background Among the renewed applications of psychedelic medicines in psychiatry, 3,4-methylenedioxymethamphetamine (MDMA)–assisted therapy for posttraumatic stress disorder (PTSD) has demonstrated the most promise in early small-scale studies. Recent exploratory analyses from prior clinical trials of MDMA-assisted therapy for PTSD have suggested that recent use of selective serotonin...

Will MDMA-assisted psychotherapy become a breakthrough in treatment-resistant post-traumatic stress disorder? A critical narrative review.

Psychiatria Polska August 31, 2022 Sandra Szafoni, Gniewko Więckiewicz, Robert Pudło et al. 9 citations

Post-traumatic stress disorder (PTSD) is a common mental health condition that begins after exposure to a traumatic event. Despite recommended various therapeutic approaches, including both pharmacotherapy and psychotherapy, treatment is not as effective as expected. Over recent years the pharmaceutical industry has not been able to offer a new approach, founded on multiple mechanisms of...

Randomised clinical non-inferiority trial of breathing-based meditation and cognitive processing therapy for symptoms of post-traumatic stress disorder in military veterans.

BMJ Open August 25, 2022 Peter J Bayley, R Jay Schulz-Heik, Julia S Tang et al.

Test whether Sudarshan Kriya Yoga (SKY) was non-inferior to cognitive processing therapy (CPT) for treating symptoms of post-traumatic stress disorder (PTSD) among veterans via a parallel randomised controlled non-inferiority trial. Outpatient Veterans Affairs healthcare centre. 85 veterans (75 men, 61% white, mean age 56.9) with symptoms of PTSD participated between October 2015 and March...

DOI: 10.1136/bmjopen-2021-056609 (opens in new tab) Full text (opens in new tab) Anxiety disorders Complementary medicine Clinical trials Mental health

Review of potential psychedelic treatments for PTSD.

Journal of the Neurological Sciences August 15, 2022 Ryan L Henner, Matcheri S Keshavan, Kevin P Hill

Post-traumatic stress disorder (PTSD) is a debilitating mental illness with limited treatment options and a high treatment dropout rate. Psychedelics, often in combination with psychotherapy, are now under investigation as a potential treatment option for a variety of psychiatric conditions including PTSD. This paper reviews the proposed mechanism of action for 3,4-Methylenedioxymethamphetamine...

Invisible wounds: Suturing the gap between the neurobiology, conventional and emerging therapies for posttraumatic stress disorder.

European Neuropsychopharmacology August 2022 Xénia Gonda, Péter Döme, Berta Erdelyi-Hamza et al.

A sharp increase in the prevalence of neuropsychiatric disorders, including major depression, anxiety, substance use disorders and posttraumatic stress disorder (PTSD) has occurred due to the traumatic nature of the persisting COVID-19 global pandemic. PTSD is estimated to occur in up to 25% of individuals following exposure to acute or chronic trauma, and the pandemic has inflicted both forms...

A Manualized Occupational Therapy Mindfulness Module for Clients with PTSD

August 1, 2022 M María de Los Ángeles Ramírez

Posttraumatic stress disorder (PTSD) adversely impacts an individual’s functioning across areas of daily occupation. There is a paucity of literature addressing occupational therapy (OT) for people with PTSD. The literature has advocated for the development of a manualized OT intervention with the inclusion of mindfulness as one of its components. To date, a mindfulness-based OT treatment guide...

Interoception Underlies Therapeutic Effects of Mindfulness Meditation for Posttraumatic Stress Disorder: A Randomized Clinical Trial.

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging August 1, 2022 Seung Suk Kang, Scott R Sponheim, Kelvin O Lim

Mindfulness-based interventions have proven efficacy in treating posttraumatic stress disorder (PTSD), but the neurobiological mechanism underlying the therapeutic effects is unknown. As mindfulness meditation cultivates attention to the present moment and bodily sensations, neural functions related to interoception (i.e., central processes of bodily signals) might be such a mechanism. We...

Visual phenomenology in schizophrenia and post-traumatic stress disorder: an exploratory study.

BJPsych Open July 25, 2022 Deborah Wearne, Jeremiah Ayalde, Guy Curtis et al. 10 citations

Visual experiences such as hallucinations are commonly reported by people with psychosis, psychological trauma and dissociative states, although questions remain about their similarities and differences. For diagnostic and therapeutic purposes, clinical research must better delineate and compare the characteristics of these experiences in post-traumatic stress disorder (PTSD) and in...

DOI: 10.1192/bjo.2022.544 (opens in new tab) Full text (opens in new tab) PTSD Visual hallucinations Dissociation Schizophrenia +1

Self-treatment of psychosis and complex post-traumatic stress disorder with LSD and DMT—A retrospective case study

Psychiatry Research Case Reports July 15, 2022 Mika Turkia 14 citations

This article describes a case of a teenager with early complex trauma due to chronic domestic violence. Cannabis use triggered auditory hallucinations, after which the teenager was diagnosed with an acute schizophrenia-like psychotic disorder. Antipsychotic medication did not fully resolve symptoms. Eventually the teenager chose to self-medicate with LSD in order to resolve a suicidal...

DOI: 10.1016/j.psycr.2022.100029 (opens in new tab) Cannabis Psychosis Antipsychotic Schizophrenia object-oriented programming +2

Efficacy and Safety of Intranasal Esketamine in Patients With Treatment-Resistant Depression and Comorbid Chronic Post-traumatic Stress Disorder: Open-Label Single-Arm Pilot Study

Frontiers in Psychiatry July 8, 2022 Maud Rothärmel, Cherifa Benosman, Wissam El-Hage et al. 31 citations

Introduction: Major depressive disorder (MDD) is more likely to resist to usual treatment when it is associated with post-traumatic stress disorder (PTSD). Capitalizing on the effect of ketamine in both treatment-resistant depression (TRD) and PTSD, we conducted a study in order to assess the efficacy of intranasal (IN) Esketamine in patients having TRD with comorbid PTSD. Materials and...

Decreased Posttraumatic Stress Disorder Symptoms Following Lucid Dream Healing Workshop

PsyArXiv July 7, 2022 Garret Yount preprint

Objective: Recent investigations of lucid dreams – dreams with a veridical awareness of dreaming - suggest that this unique form of dreaming may be useful for promoting healing due to the lucid dreamer’s capacity for goal-directed action in the dream. Methods: Following a prospective, within-participant research design, 49 adults experiencing chronic post-traumatic stress disorder (PTSD)...

Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial.

Neuropsychopharmacology July 2022 Chadi G. Abdallah, John D Roache, Ralitza Gueorguieva et al.

This study tested the efficacy of repeated intravenous ketamine doses to reduce symptoms of posttraumatic stress disorder (PTSD). Veterans and service members with PTSD (n = 158) who failed previous antidepressant treatment were randomized to 8 infusions administered twice weekly of intravenous placebo (n = 54), low dose (0.2 mg/kg; n = 53) or standard dose (0.5 mg/kg; n = 51) ketamine....

Characteristics of Sleep Paralysis and Its Association with Anxiety Symptoms, Perceived Stress, PTSD, and Other Variables Related to Lifestyle in Selected High Stress Exposed Professions.

International Journal of Environmental Research and Public Health June 25, 2022 Paulina Wróbel-knybel, Michał Flis, Joanna Róg et al.

Sleep paralysis (SP) is a hypnagogic or hypnopompic state associated with the inability to move while conscious. Recurrent isolated sleep paralysis (RISP) is a type of REM parasomnia. Individuals experiencing anxiety disorders, PTSD, exposure to chronic stress, or shift work are at risk of developing this sleep disorder. This study aimed to assess: (1) the prevalence, frequency, and...

MDMA-assisted therapy for posttraumatic stress disorder: A pooled analysis of ethnoracial differences in efficacy and safety from two Phase 2 open-label lead-in trials and a Phase 3 randomized, blinded placebo-controlled trial

Journal of Psychopharmacology June 21, 2022 Terence H. W. Ching, Monnica T. Williams, Julie B. Wang et al. 29 citations

Background: Limited ethnoracial diversity in previous ±3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) trials for posttraumatic stress disorder (PTSD) has prompted questions concerning whether Black, Indigenous, and People of Color (BIPOC) also benefit from this treatment. Methods: Secondary analysis was conducted using a modified intent-to-treat sample pooled from two Phase 2...

Risk factors of sleep paralysis in a population of Polish students.

BMC Psychiatry June 7, 2022 Paulina Wróbel-knybel, Michał Flis, Joanna Róg et al. 9 citations

Sleep paralysis (SP) is a transitional dissociative state associated with the REM sleep phase that affects approximately 28.3% of the student population during their lifetime. The reasons for the high prevalence of SP in the student population are not entirely clear. Research indicates possible influencing factors such as the intensification of anxiety symptoms, a tendency to worry, the...

Methylenedioxymethamphetamine-assisted Psychotherapy For Posttraumatic Stress Disorder: A Review

European Psychiatry June 1, 2022 J. Sá Couto, B. Da Luz, J. Rodrigues et al.

IntroductionPosttraumatic stress disorder (PTSD) is a psychiatric condition which can be developed following traumatic experience. Treatment guidelines have long considered psychotherapy as a first line treatment. Despite that, PTSD remains an illness with high rates of comorbidity. Therefore, exploring novel therapies is of utmost importance.ObjectivesClarifying methylenedioxymethamphetamine...

MDMA-Assisted Therapy for Treatment-Resistant Posttraumatic Stress Disorder (PTSD) – One step further toward a patient-centered treatment pathway

European Psychiatry June 1, 2022 S. Pratas Penedos, M.j. Freire, I. Fonseca et al.

IntroductionPTSD is a chronic, debilitating condition with limited treatment efficacy. Accessing traumatic memories often leads to overwhelming distress, impacting treatment process. Current approved pharmacological treatments have exhibited small to moderate effects when compared with placebo. Evidence suggests 3,4,-methylene-dioxymethamphetamine(MDMA)-assisted psychotherapy as a viable option...

Evidence for altered neural activity patterns after MDMA-assisted therapy in adults with chronic and severe post-traumatic stress disorder: a pilot study

medRxiv May 27, 2022 S. P. Singleton, J. B. Wang, M. Mithoefer et al. preprint

3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) has demonstrated promise in multiple clinical trials. MDMA is hypothesized to facilitate the therapeutic process, in part, by decreasing fear response during fear memory processing while increasing extinction learning retention. The acute administration of MDMA in healthy controls modifies...

Psychoactive Drugs in the Management of Post Traumatic Stress Disorder: A Promising New Horizon

Cureus May 23, 2022 Kawther N Elsouri, Sahand Kalhori, Diego Colunge et al. 15 citations

Post-traumatic stress disorder (PTSD) is an anxiety disorder that often presents after exposure to a traumatic, life-threatening event. Experiencing a traumatic event is not rare, with inciting incidents ranging from being burglarized to politically motivated genocide. While traditional psychopharmacology and psychotherapy are the mainstays of the treatment of PTSD currently, psychoactive drugs...